No material corporate news briefings have been provided for Amgen Inc. as of the generation date of 2026-05-24. The report is principally driven by notable institutional position changes recorded in recent 13F filings and is supplemented by the most recent quarterly financial data and insider transaction disclosures.
Amgen's trailing twelve-month revenue stood at $37.22 billion as of 2026-03-31, representing year-over-year growth of 5.76%. Net income for the same period was $7.80 billion, with a net margin of 20.96% and an operating margin of 28.39%. Gross margin was recorded at 48.58%. Earnings per share grew 4.38% year-over-year. The company held $12.04 billion in cash against total debt of $59.32 billion. Market capitalisation was approximately $183.05 billion, with a price-to-earnings ratio of 23.6 [SEC 10-Q - AMGN - 2026-03-31].
Insider activity over the past 30 days comprised 68 transactions with a net selling direction and a net disposal value of approximately $400,451 [SEC Form 4 - AMGN - 2026-05]. On the institutional side, Bridgewater added 389% to its AMGN position, while Millennium added 47%. Citadel reduced its position by 9.4% and AQR Capital reduced its position by 30% [SEC 13F - Citadel - Q1 2026; SEC 13F - Millennium - Q1 2026; SEC 13F - AQR Capital - Q1 2026; SEC 13F - Bridgewater - Q1 2026].
The prevailing macro environment features a 10-year US Treasury yield of 4.57% and a 2-year yield of 4.08%, producing a normal yield curve spread of 49 basis points [FRED DGS10; FRED DGS2]. The divergent institutional positioning changes — most notably Bridgewater's substantial addition and AQR's material reduction — constitute the primary trigger for this report.